688382 益方生物
已收盘 12-17 15:00:01
资讯
新帖
简况
12月15日益方生物跌7.20%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 12-15 15:35
12月15日益方生物跌7.20%,汇添富医疗服务灵活配置混合A基金重仓该股
12月12日益方生物现1笔大宗交易 机构净买入419.32万元
证券之星 · 12-12
12月12日益方生物现1笔大宗交易 机构净买入419.32万元
12月10日益方生物涨5.75%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 12-10
12月10日益方生物涨5.75%,汇添富医疗服务灵活配置混合A基金重仓该股
益方生物涨5.75%,天风证券三个月前给出“买入”评级
证券之星 · 12-10
益方生物涨5.75%,天风证券三个月前给出“买入”评级
益方生物(688382)披露拟发行H股并在港交所上市,12月09日股价下跌2.96%
证券之星 · 12-09
益方生物(688382)披露拟发行H股并在港交所上市,12月09日股价下跌2.96%
益方生物:拟筹划发行H股股票并在香港联交所上市
每日经济新闻 · 12-09
益方生物:拟筹划发行H股股票并在香港联交所上市
【机构调研记录】长盛基金调研技源集团、益方生物
证券之星 · 12-02
【机构调研记录】长盛基金调研技源集团、益方生物
【机构调研记录】宏利基金调研益方生物
证券之星 · 12-02
【机构调研记录】宏利基金调研益方生物
11月28日益方生物涨5.93%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 11-28
11月28日益方生物涨5.93%,汇添富医疗服务灵活配置混合A基金重仓该股
益方生物涨5.93%,天风证券二个月前给出“买入”评级
证券之星 · 11-28
益方生物涨5.93%,天风证券二个月前给出“买入”评级
11月21日益方生物跌5.21%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 11-21
11月21日益方生物跌5.21%,汇添富医疗服务灵活配置混合A基金重仓该股
11月13日益方生物涨10.19%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 11-13
11月13日益方生物涨10.19%,汇添富医疗服务灵活配置混合A基金重仓该股
益方生物涨10.19%,天风证券二个月前给出“买入”评级
证券之星 · 11-13
益方生物涨10.19%,天风证券二个月前给出“买入”评级
“吃药”行情归来?4600亿巨头成功扭亏,港A创新药全线沸腾
格隆汇 · 11-13
“吃药”行情归来?4600亿巨头成功扭亏,港A创新药全线沸腾
11月7日益方生物跌5.53%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 11-07
11月7日益方生物跌5.53%,汇添富医疗服务灵活配置混合A基金重仓该股
11月5日益方生物跌6.28%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 11-05
11月5日益方生物跌6.28%,汇添富医疗服务灵活配置混合A基金重仓该股
每周股票复盘:益方生物(688382)股价涨幅达15%上榜龙虎榜
证券之星 · 11-02
每周股票复盘:益方生物(688382)股价涨幅达15%上榜龙虎榜
10月31日益方生物(688382)龙虎榜数据:机构净买入8722.16万元,北向资金净卖出5328.21万元
证券之星 · 10-31
10月31日益方生物(688382)龙虎榜数据:机构净买入8722.16万元,北向资金净卖出5328.21万元
股市必读:益方生物(688382)股东户数1.24万户,较上期增加26.17%
证券之星 · 10-31
股市必读:益方生物(688382)股东户数1.24万户,较上期增加26.17%
图解益方生物三季报:第三季度单季净利润同比增长31.99%
证券之星 · 10-29
图解益方生物三季报:第三季度单季净利润同比增长31.99%
加载更多
公司概况
公司名称:
益方生物科技(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2022-07-25
主营业务:
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。
发行价格:
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物","latestPrice":29,"timestamp":1765954801000,"preClose":29.25,"halted":0,"volume":7441678,"delay":0,"changeRate":-0.0085,"floatShares":418000000,"shares":578000000,"eps":-0.2011,"marketStatus":"已收盘","change":-0.25,"latestTime":"12-17 15:00:01","open":29.03,"high":29.62,"low":28.45,"amount":216000000,"amplitude":0.04,"askPrice":29.01,"askSize":8,"bidPrice":29,"bidSize":311,"shortable":0,"etf":0,"ttmEps":-0.2011,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":29.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":32.18,"lowLimit":26.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":578348491,"isCdr":false,"pbRate":10.07,"roa":"--","roe":"--","epsLYR":-0.4167,"committee":0.287879,"marketValue":16772000000,"turnoverRate":0.0178,"status":1,"afterMarket":{"amount":0,"volume":0,"close":29,"buyVolume":2400,"sellVolume":0,"time":1765956837768,"indexStatus":"已收盘 12-17 15:30:00","preClose":29.25},"floatMarketCap":12111000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2591600615","title":"12月15日益方生物跌7.20%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591600615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591600615?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:35","pubTimestamp":1765784131,"startTime":"0","endTime":"0","summary":"证券之星消息,12月15日益方生物跌7.20%,收盘报29.0元,换手率3.56%,成交量14.88万手,成交额4.42亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.841,较上一交易日下跌0.86%,近一年上涨40.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2590773985","title":"12月12日益方生物现1笔大宗交易 机构净买入419.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590773985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590773985?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:58","pubTimestamp":1765533528,"startTime":"0","endTime":"0","summary":"证券之星消息,12月12日益方生物发生大宗交易,交易数据如下:大宗交易成交价格31.25元,成交13.42万股,成交金额419.32万元,买方营业部为机构专用,卖方营业部为瑞银证券有限责任公司上海花园石桥路证券营业部。近三个月该股共发生7笔大宗交易,合计成交4.87万手,折价成交6笔。截至2025年12月12日收盘,益方生物报收于31.25元,上涨2.46%,换手率6.76%,成交量28.22万手,成交额8.53亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2590309423","title":"12月10日益方生物涨5.75%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309423?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:32","pubTimestamp":1765351973,"startTime":"0","endTime":"0","summary":"证券之星消息,12月10日益方生物涨5.75%,收盘报29.81元,换手率4.19%,成交量17.51万手,成交额5.13亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.845,较上一交易日下跌0.38%,近一年上涨38.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000019232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2590330941","title":"益方生物涨5.75%,天风证券三个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2590330941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590330941?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:32","pubTimestamp":1765351963,"startTime":"0","endTime":"0","summary":"今日益方生物(688382)涨5.75%,收盘报29.81元。2025年9月10日,天风证券研究员杨松,曹文清发布了对益方生物的研报《TYK2抑制剂具备BIC潜力,多项适应症临床同步推进》,该研报对益方生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为62.89%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的崔文亮。益方生物(688382)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000019228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","688382"],"gpt_icon":0},{"id":"2590342885","title":"益方生物(688382)披露拟发行H股并在港交所上市,12月09日股价下跌2.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342885","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342885?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:17","pubTimestamp":1765289848,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘,益方生物报收于28.19元,较前一交易日下跌2.96%,最新总市值为163.04亿元。该股当日开盘29.2元,最高30.46元,最低28.13元,成交额达4.65亿元,换手率为3.83%。会议采取现场投票与网络投票相结合的方式,股权登记日为2025年12月18日。其中多项议案涉及特别决议及中小投资者单独计票。关联股东需回避表决的议案为投保董事、高级管理人员及招股说明书责任保险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239","HEXmain"],"gpt_icon":0},{"id":"2590345884","title":"益方生物:拟筹划发行H股股票并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345884","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590345884?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:16","pubTimestamp":1765278960,"startTime":"0","endTime":"0","summary":"每经AI快讯,12月9日,益方生物(688382.SH)公告称,公司拟于境外发行股份(H股),并申请在香港联交所主板挂牌上市。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-09/doc-inhafezw2550530.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-09/doc-inhafezw2550530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2588701456","title":"【机构调研记录】长盛基金调研技源集团、益方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701456?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:05","pubTimestamp":1764633941,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及12月1日披露的机构调研信息,长盛基金近期对2家上市公司进行了调研,相关名单如下:1)技源集团 调研纪要:公司通过精加工优化氨糖原料可压性,形成技术优势与品牌溢价,支撑高毛利率。长盛基金成立于1999年,截至目前,资产管理规模976.25亿元,排名64/211;资产管理规模640.97亿元,排名67/211;管理公募基金数141只,排名57/211;旗下公募基金经理23人,排名63/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200003774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603262","688382","BK0226","BK0239"],"gpt_icon":0},{"id":"2588701171","title":"【机构调研记录】宏利基金调研益方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701171?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:05","pubTimestamp":1764633920,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及12月1日披露的机构调研信息,宏利基金近期对1家上市公司进行了调研,相关名单如下:1)益方生物 调研纪要:D-2570针对溃疡性结肠炎的II期临床已完成首例患者给药,银屑病III期临床正推进中。旗下最近一年表现最佳的公募基金产品为宏利成长混合,最新单位净值为3.7,近一年增长103.54%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200003738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2586020154","title":"11月28日益方生物涨5.93%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586020154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586020154?lang=zh_cn&edition=full","pubTime":"2025-11-28 15:33","pubTimestamp":1764315221,"startTime":"0","endTime":"0","summary":"证券之星消息,11月28日益方生物涨5.93%,收盘报29.48元,换手率4.95%,成交量20.67万手,成交额5.9亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.878,较上一交易日下跌0.48%,近一年上涨40.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800016737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2586201993","title":"益方生物涨5.93%,天风证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2586201993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586201993?lang=zh_cn&edition=full","pubTime":"2025-11-28 15:33","pubTimestamp":1764315209,"startTime":"0","endTime":"0","summary":"今日益方生物(688382)涨5.93%,收盘报29.48元。2025年9月10日,天风证券研究员杨松,曹文清发布了对益方生物的研报《TYK2抑制剂具备BIC潜力,多项适应症临床同步推进》,该研报对益方生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为62.89%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的崔文亮。益方生物(688382)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800016721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","601162"],"gpt_icon":0},{"id":"2585190835","title":"11月21日益方生物跌5.21%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190835?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:46","pubTimestamp":1763711209,"startTime":"0","endTime":"0","summary":"证券之星消息,11月21日益方生物跌5.21%,收盘报25.47元,换手率3.11%,成交量13.01万手,成交额3.39亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.825,较上一交易日上涨0.5%,近一年上涨39.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2583554217","title":"11月13日益方生物涨10.19%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554217?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:28","pubTimestamp":1763022536,"startTime":"0","endTime":"0","summary":"证券之星消息,11月13日益方生物涨10.19%,收盘报28.98元,换手率5.94%,成交量24.83万手,成交额7.06亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.811,较上一交易日上涨1.97%,近一年上涨37.09%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2583554768","title":"益方生物涨10.19%,天风证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554768?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:28","pubTimestamp":1763022527,"startTime":"0","endTime":"0","summary":"今日益方生物(688382)涨10.19%,收盘报28.98元。2025年9月10日,天风证券研究员杨松,曹文清发布了对益方生物的研报《TYK2抑制剂具备BIC潜力,多项适应症临床同步推进》,该研报对益方生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为62.89%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的崔文亮。益方生物(688382)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","601162"],"gpt_icon":0},{"id":"2583853558","title":"“吃药”行情归来?4600亿巨头成功扭亏,港A创新药全线沸腾","url":"https://stock-news.laohu8.com/highlight/detail?id=2583853558","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583853558?lang=zh_cn&edition=full","pubTime":"2025-11-13 14:18","pubTimestamp":1763014725,"startTime":"0","endTime":"0","summary":"机构:中国创新药产业已进入2.0时代","market":"us","thumbnail":"https://static.tigerbbs.com/a9cdeabfc0af4ed4ad7c24a7818b7af3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a9cdeabfc0af4ed4ad7c24a7818b7af3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f6068c36e82c4ed544af336a63a9d021","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3190454","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1141","BK1574","BK1589","01177","BK1521","IE00BZ08YR35.GBP","06978","02268","IE00BZ08YT58.USD","HK0000165453.HKD","BK0201","LU2488822045.USD","IE00BZ08YS42.EUR","300497","300584","BK1161","SG9999014674.SGD","BK0239","BK1191","688382","01672","002864","BK1515"],"gpt_icon":1},{"id":"2581007265","title":"11月7日益方生物跌5.53%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581007265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581007265?lang=zh_cn&edition=full","pubTime":"2025-11-07 16:18","pubTimestamp":1762503483,"startTime":"0","endTime":"0","summary":"证券之星消息,11月7日益方生物跌5.53%创60日新低,收盘报24.92元,换手率3.79%,成交量15.85万手,成交额4.05亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.794,较上一交易日下跌0.11%,近一年上涨38.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700024850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2581749464","title":"11月5日益方生物跌6.28%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581749464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581749464?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:28","pubTimestamp":1762331307,"startTime":"0","endTime":"0","summary":"证券之星消息,11月5日益方生物跌6.28%,收盘报27.0元,换手率5.1%,成交量21.28万手,成交额5.84亿元。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共88家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为30.61亿元,最新净值1.81,较上一交易日下跌3.1%,近一年上涨40.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500027446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2580478739","title":"每周股票复盘:益方生物(688382)股价涨幅达15%上榜龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478739","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580478739?lang=zh_cn&edition=full","pubTime":"2025-11-02 01:45","pubTimestamp":1762019113,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,益方生物报收于30.3元,较上周的26.87元上涨12.77%。本周,益方生物10月31日盘中最高价报30.98元。本周关注点来自交易信息汇总:益方生物因日收盘价涨幅达15%登上龙虎榜。此次是近5个交易日内第1次上榜。股本股东变化股东户数变动近日益方生物披露,截至2025年9月30日公司股东户数为1.24万户,较6月30日增加2562.0户,增幅为26.17%。户均持股数量由上期的5.91万股减少至4.68万股,户均持股市值为145.66万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2579454588","title":"10月31日益方生物(688382)龙虎榜数据:机构净买入8722.16万元,北向资金净卖出5328.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454588","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579454588?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:48","pubTimestamp":1761904095,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年10月31日公布的交易公开信息显示,益方生物因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年10月31日收盘,益方生物报收于30.3元,上涨15.3%,换手率7.78%,成交量32.48万手,成交额9.45亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入8722.16万元,北向资金合计净卖出5328.21万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100037751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2579610189","title":"股市必读:益方生物(688382)股东户数1.24万户,较上期增加26.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579610189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579610189?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:36","pubTimestamp":1761863763,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘,益方生物报收于26.28元,上涨0.81%,换手率3.34%,成交量13.97万手,成交额3.66亿元。交易信息汇总资金流向10月30日主力资金净流出979.95万元,占总成交额2.68%;游资资金净流入1857.25万元,占总成交额5.07%;散户资金净流出877.3万元,占总成交额2.4%。股本股东变化股东户数变动截至2025年9月30日,益方生物股东户数为1.24万户,较6月30日增加2562.0户,增幅26.17%;户均持股数量由上期的5.91万股下降至4.68万股,户均持股市值为145.66万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2579903560","title":"图解益方生物三季报:第三季度单季净利润同比增长31.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579903560","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579903560?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:07","pubTimestamp":1761739671,"startTime":"0","endTime":"0","summary":"证券之星消息,益方生物2025年三季报显示,前三季度公司主营收入3089.35万元,同比上升61.27%;归母净利润-1.81亿元,同比上升40.59%;扣非净利润-1.92亿元,同比上升38.72%;其中2025年第三季度,公司单季度主营收入1172.96万元,同比上升173.86%;单季度归母净利润-6195.27万元,同比上升31.99%;单季度扣非净利润-6290.53万元,同比上升36.17%;负债率5.61%,投资收益47.8万元,财务费用-2034.52万元,毛利率86.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900041113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765994636583,"stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":0.0737},{"period":"3month","weight":-0.155},{"period":"6month","weight":-0.0782},{"period":"1year","weight":1.2853},{"period":"ytd","weight":1.1805}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12352人(较上一季度增加26.17%)","perCapita":"33810股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57834万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物,688382,益方生物股票,益方生物股票老虎,益方生物股票老虎国际,益方生物行情,益方生物股票行情,益方生物股价,益方生物股市,益方生物股票价格,益方生物股票交易,益方生物股票购买,益方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}